Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation

dc.authorid0000-0002-6423-0927
dc.authorid0000-0003-1194-0164
dc.contributor.authorAtmaca, Mustafa
dc.contributor.authorGulhan, Bora
dc.contributor.authorAtayar, Emine
dc.contributor.authorBayazit, Aysun Karabay
dc.contributor.authorCandan, Cengiz
dc.contributor.authorArici, Mustafa
dc.contributor.authorTopaloglu, Rezan
dc.date.accessioned2025-05-10T19:52:23Z
dc.date.issued2019
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractADCK4-related glomerulopathy is a recently recognized clinical entity associated with insidious onset in young children and a high potential to progress to chronic kidney disease in adolescents. Early initiation of exogenous coenzyme Q10 (CoQ10) supplementation in the asymptomatic period could be protective on renal functions. In the present study, we aimed to investigate long-term follow-up of patients that we have diagnosed during the asymptomatic period and in whom we started CoQ10 treatment. We analyzed long-term effects of CoQ10 on proteinuria and estimated glomerular filtration rate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male) from 6 different families were included. The mean age at diagnosis and at last visit were 16.8 +/- 11.2 years and 20.7 +/- 11.7 years, respectively. None of the patients had extrarenal system involvement. At the time of initiation of treatment; median eGFR was 107.8 ml/min/1.73 m(2), median proteinuria was 1008 mg/m(2)/day. After a median follow-up period of 25.3 +/- 5.8 months, median proteinuria decreased to 318.5 mg/m(2)/day (p=0.03) and median eGFR remained stable at 99.6 ml/min/1.73 m(2) (p=0.21). Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective.
dc.description.sponsorshipEuropean Community [2012-305608]
dc.description.sponsorshipThe research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 2012-305608 (EURenOmics).
dc.identifier.doi10.24953/turkjped.2019.05.003
dc.identifier.endpage663
dc.identifier.issn0041-4301
dc.identifier.issue5
dc.identifier.pmid32104996
dc.identifier.scopus2-s2.0-85080059845
dc.identifier.scopusqualityQ3
dc.identifier.startpage657
dc.identifier.trdizinid353321
dc.identifier.urihttps://doi.org/10.24953/turkjped.2019.05.003
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/353321
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12404
dc.identifier.volume61
dc.identifier.wosWOS:000518430400003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish J Pediatrics
dc.relation.ispartofTurkish Journal of Pediatrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectSteroid-resistant nephrotic syndrome
dc.subjectADCK4 mutation
dc.subjectCoQ10 treatment
dc.titleLong-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12404.pdf
Boyut:
940.45 KB
Biçim:
Adobe Portable Document Format